During Thursday’s Current trade, Shares of DCT Industrial Trust Inc (NYSE:DCT), lost -1.03% to $34.56.
CT Industrial Trust® (DCT), a leading industrial real estate company, declared financial results for the quarter ending June 30, 2015.
Funds from operations, as adjusted, attributable to common stockholders and unitholders (“FFO”) for Q2 2015 totaled $44.2 million, or $0.47 per diluted share, contrast with $41.6 million, or $0.48 per diluted share, for Q2 2014, a decrease of 2.1 percent per diluted share. These results exclude $0.2 million and $0.6 million of acquisition costs for the quarters ending June 30, 2015 and 2014, respectively. FFO comprises a one-time, $3.4 million charge (counting associated costs) due to the formerly stated fraud. This charge reduced FFO by $0.04 per diluted share for the quarter.
Net income attributable to common stockholders for Q2 2015 was $18.3 million, or $0.20 per diluted share, contrast to $6.8 million, or $0.08 per diluted share, stated for Q2 2014.
DCT Industrial Trust Inc. operates as a publicly owned real estate investment trust. The firm provides its services to companies. Through its fund, it engages in the ownership, operation, and development of real estate properties. The firm specializes in the ownership, acquisition, development, and administration of institutional capital administration program. It invests in the real estate markets of United States and Mexico. The firm is also invests in selected international markets.
Shares of ServiceNow Inc (NYSE:NOW), declined -2.51% to $74.92, during its current trading session.
ServiceNow® (NOW), the enterprise cloud company, declared the financial results for its second quarter 2015.
Second Quarter 2015 Results:
- Revenues of $246.7 million, an enhance of 48% year-over-year and 59% in constant currency.
- GAAP net loss of $61.9 million, or a loss of $0.40 per basic and diluted share, contrast to a GAAP net loss of $50.4 million, or a loss of $0.35 per basic and diluted share, in the second quarter of 2014.
- Non-GAAP net income of $7.3 million, or income of $0.05 per basic share and $0.04 per diluted share, contrast to a non-GAAP net loss of $9.4 million, or a loss of $0.07 per basic and diluted share, in the second quarter of 2014.
- Calculated billings were $281.4 million, increasing 50% year-over-year and 62% in constant currency.
- Added 21 net new Global 2000 customers, bringing the total to 566.
- For a reconciliation of these GAAP and non-GAAP financial measures, please see the table entitled “Results of Operations GAAP to Non-GAAP Reconciliation” comprised of at the end of this release.
ServiceNow, Inc. provides cloud-based solutions that define, structure, manage, and automate services to enterprise operations in North America, Europe, the Middle East, Africa, the Asia Pacific, and other countries. The company offers service administration solutions, counting incident administration, problem administration, change administration, request administration, and cost administration, in addition to service catalog and knowledge base; and IT, HR, facilities, and field service administration solutions.
Lipocine Inc (NASDAQ:LPCN), during its Thursday’s current trading session decreased -1.54% to $15.94.
Lipocine Inc. (LPCN), a specialty pharmaceutical company, declared financial results for the quarter ended June 30, 2015, in addition to recent operational highlights.
Quarterly and Recent Highlights
- Delivered top-line 52-week safety results from its Study of Oral Androgen Replacement cardiac (“SOAR”) pivotal Phase 3 evaluating efficacy and safety of LPCN 1021, an oral testosterone product candidate, in hypogonadal men with low testosterone. Overall, LPCN 1021 was well tolerated with no hepatic, cardiac, gastrointestinal or drug-related SAE’s stated.
- Declared the successful completion of its labeling “food effect study” for LPCN 1021, which was conducted per the U.S. Food and Drug Administration (“FDA”) requirement for submitting the New Drug Application (“NDA”) for LPCN 1021. The top-line results of the study indicated that bioavailability of testosterone from LPCN 1021 is not affected by changes in meal fat content.
- Declared its development plans for LPCN 1107, the company’s oral hydroxyprogesterone caproate (“HPC”) product candidate. Based on FDA Type C written feedback, Lipocine intends to conduct a multiple-dose pharmacokinetic (“PK”) dose selection study in pregnant women. The PK dose selection study is planned to commence in the fourth quarter of 2015.
- During the quarter, the FDA granted Lipocine orphan drug designation for LPCN 1107.
- Accomplished an underwritten public offering of 5,347,500 shares of its common stock at $6.50 per share for gross proceeds of $34.8 million. Lipocine received net proceeds of about $32.4 million, after deducting the underwriters’ discounts and other estimated offering expenses.
Lipocine Inc., a specialty pharmaceutical company, develops pharmaceutical products using its oral drug delivery technology in the areas of men’s and women’s health. The company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate, LPCN 1021, an oral testosterone replacement therapy designed for twice-a-day dosing, is in Phase III clinical study.
Finally, AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), decreased -0.72%, to $63.80.
AMAG Pharmaceuticals, Inc. (AMAG) declared that it has priced its formerly declared underwritten public offering of common stock comprising of 3,150,000 shares at a public offering price of $63.75 per share. Gross proceeds to AMAG from this offering are predictable to be about $201 million. AMAG intends to use the net proceeds from this offering for the expansion and diversification of its product portfolio through the in-license or purchase of additional pharmaceutical products or companies, such as Cord Blood Registry (CBR), to refinance certain existing indebtedness, to pay various fees and expenses incurred in connection with the CBR acquisition and related financing transactions, in addition to for general corporate purposes.
AMAG has granted the underwriters a 30-day option to purchase up to an additional 472,500 shares of common stock offered in the public offering. All of the shares in the offering will be sold by AMAG.
AMAG Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that focuses on maternal health, anemia, and cancer supportive care. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women with a singleton pregnancy; Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the administration of oral mucocitis/stomatiits and various types of oral wounds.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
